Stryker Corporation SYK
At closeNov 6, 2026, 5:05 PM EST
After hours · Nov 6, 5:05 PM ET
- YTD
- -7.28%
- 1 year
- -7.90%
Discussion (6)
Sign in to join the discussion
I advise new and inexperienced traders who are looking for a way to invest and make money while still being unable to profit from stocks, I know of one financial industry specialist who can help an insured accurate prediction availability connect with Laura Ben Wesley via her ????????+1(541)310-7087
Robert Henry SYK 2 years ago #2investing is the only way to financial Freedom, Best regards goes to the company administrators for my social switchover and also to my account manager Eric Tred1 on l·ńธ ƭa¤gram for all the help, I have been into his platform for 6 months now I intended to keep it low cause I wasn't sure if the platform was real till after 6 months I can now proudly tell you that this platform is one of the best Bitcoin investment platform, It is well known verified platform which I will also like you to join this platform and start earning like me and other investors, I started with $300 but now I can proudly boost of over $5000 from this company and the best of it all is that you can withdraw at anytime as long as your investment time is over with the package you chose....
GFABCSS SYK 4 years ago #4$SYK this is going to tank badly
How many knew that Ocugen had a partnership which contractually GUARANTEES them revenues from Covid19 Antibody Testing?
(re: page 22 of annual report):
https://www.sec.gov/Archives/edgar/data/1372299/000110465920053502/tm2017927-1_10ka.htm
Collaboration with Advaite, Inc.
In April 2020, the Company entered into an agreement with Advaite, Inc., (Advaite) to provide certain support services for Advaite's development of a diagnostic test kit that is designed to detect antibodies to COVID-19. ...{Ocugen}... will receive tiered royalty payments based on cumulative net sales of the test kit.
The projected market for Covid diagnostic testing is $61B AND GROWING!
MORE IMPORTANTLY Advaite is NOW MOVING on Covid Antibody Testing!
https://www.linkedin.com/mwlite/company/advaite
*
The BEAUTY here:
NOBODY KNOWS Ocugen will be collecting potentially BILLION$ in COVID DIAGNOSTICS revenue! They NEVER did a PRESS RELEASE!
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!